Positive News SentimentPositive NewsNASDAQ:GNTA Genenta Science (GNTA) Stock Price, News & Analysis $3.05 -0.05 (-1.61%) As of 06/30/2025 02:53 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Genenta Science Stock (NASDAQ:GNTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genenta Science alerts:Sign Up Key Stats Today's Range$3.05▼$3.2950-Day Range$3.05▼$5.0152-Week Range$2.79▼$7.28Volume4,856 shsAverage Volume16,240 shsMarket Capitalization$55.78 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingBuy Company OverviewGenenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Read More… Genenta Science Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreGNTA MarketRank™: Genenta Science scored higher than 52% of companies evaluated by MarketBeat, and ranked 553rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGenenta Science has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenenta Science has received no research coverage in the past 90 days.Read more about Genenta Science's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Genenta Science are expected to decrease in the coming year, from ($0.93) to ($1.07) per share.Price to Book Value per Share RatioGenenta Science has a P/B Ratio of 4.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of Genenta Science has been sold short.Short Interest Ratio / Days to CoverGenenta Science has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genenta Science has recently increased by 40.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenenta Science does not currently pay a dividend.Dividend GrowthGenenta Science does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of Genenta Science has been sold short.Short Interest Ratio / Days to CoverGenenta Science has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genenta Science has recently increased by 40.00%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentGenenta Science has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Genenta Science this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genenta Science insiders have not sold or bought any company stock.Percentage Held by Insiders28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.13% of the stock of Genenta Science is held by institutions.Read more about Genenta Science's insider trading history. Receive GNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter. Email Address GNTA Stock News HeadlinesGenenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals1 hour ago | globenewswire.comGNTA Genenta Science S.p.A.May 30, 2025 | seekingalpha.comGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an epic bull rally in gold. JP Morgan and Goldman Sachs have a price target of $4,000. My research tells me gold could surpass $5,000 in the coming months. Folks using a very specific gold strategy since the 80s could have made more than 60 TIMES their money. Today, you can take advantage of a similar setup for around $10 | Stansberry Research (Ad)Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapiesMay 7, 2025 | globenewswire.comGenenta Showcases Strategic Vision at Premier Biotech Forum in QatarApril 15, 2025 | globenewswire.comGenenta Science announces EUR 20M financing to expand pipelineMarch 21, 2025 | markets.businessinsider.comGenenta Science Secures €20 Million Convertible Bond Financing for Oncology ResearchMarch 19, 2025 | tipranks.comGenenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival RatesMarch 19, 2025 | globenewswire.comSee More Headlines GNTA Stock Analysis - Frequently Asked Questions How have GNTA shares performed this year? Genenta Science's stock was trading at $4.35 at the start of the year. Since then, GNTA stock has decreased by 29.9% and is now trading at $3.05. View the best growth stocks for 2025 here. When did Genenta Science IPO? Genenta Science (GNTA) raised $28 million in an IPO on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share. How do I buy shares of Genenta Science? Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genenta Science own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genenta Science investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), PDD (PDD) and AppLovin (APP). Company Calendar Today6/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNTA CIK1838716 Webwww.genenta.com Phone39-02-2643-4681FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$25.00 Low Stock Price Target$25.00 Potential Upside/Downside+719.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.89 Quick Ratio6.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book4.12Miscellaneous Outstanding Shares18,290,000Free Float12,988,000Market Cap$55.78 million OptionableNot Optionable Beta0.73 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:GNTA) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.